✦ LIBER ✦

A phase II study of oral idarubicin in advanced recurrent or refractory ovarian carcinoma

✍ Scribed by Christopher J. Williams

Publisher: Springer
Year: 1990
Tongue: English
Weight: 169 KB
Volume: 25
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00684891

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of oral idarubicin (4-d

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

A phase II and pharmacodynamic study of

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

✍ Edwin M. Posadas; Meghan S. Liel; Virginia Kwitkowski; Lori Minasian; Andrew K. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

## Abstract ## BACKGROUND The primary objective of this study was to evaluate the biochemical effects of gefitinib on its target signal‐transduction pathways in patients with recurrent epithelial ovarian cancer (EOC). The secondary objectives included assessing clinical activity and toxicity and d

Phase II trial of vinblastine in advance

Phase II trial of vinblastine in advanced ovarian carcinoma

✍ Gregory P. Sutton; John A. Blessing; Mark D. Adelson; Parviz Hanjani 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 231 KB

A phase II trial of vinblastine in patients with refractory epithelial ovarian adenocarcinoma of the ovary was conducted by the Gynecologic Oncology Group (GOG) between March 9, 1988 and July 7, 1988. Vinblastine was administered in a dose of 9 mg/m2 intravenously every three weeks until disease pro

A phase II study of weekly cisplatin fol

A phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma

✍ Peter G. Rose; M. Steven Piver; John H. Malfetano; Trudy R. Baker; Ronald E. Hem 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB 👁 2 views

Phase II study of oxaliplatin in patient

Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma

✍ Yasuhiro Oki; Peter McLaughlin; Barbara Pro; Fredrick B. Hagemeister; Archie Ble 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Sequential topotecan and oral etoposide

Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane : Results from a multicenter Phase I/II study

✍ Bo Gronlund; Svend A. Engelholm; György Horvath; Johanna Mäenpää; Mona Ridderhei 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND The objectives of this study were to determine the maximum tolerable dose (MTD), toxicity, efficacy, and feasibility of a sequential regimen of fixed‐dose topotecan (1.00 mg/m^2^ on Days 1–5) and increasing doses of oral etoposide (50 mg, 75 mg, and 100 mg on Days 6–12 or